NEUROBO PHARMACEUTICALS INC (NRBO) Stock Price & Overview
NASDAQ:NRBO • US64132R4048
Current stock price
The current stock price of NRBO is 2.36 USD. Today NRBO is up by 0.43%. In the past month the price decreased by -10.94%. In the past year, price decreased by -34.43%.
NRBO Key Statistics
- Market Cap
- 20.343M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.00
- Dividend Yield
- N/A
NRBO Stock Performance
NRBO Stock Chart
NRBO Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to NRBO. When comparing the yearly performance of all stocks, NRBO is a bad performer in the overall market: 92.91% of all stocks are doing better.
NRBO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NRBO. While NRBO seems to be doing ok healthwise, there are quite some concerns on its profitability.
NRBO Earnings
NRBO Forecast & Estimates
8 analysts have analysed NRBO and the average price target is 27.2 USD. This implies a price increase of 1052.54% is expected in the next year compared to the current price of 2.36.
NRBO Groups
Sector & Classification
NRBO Financial Highlights
Over the last trailing twelve months NRBO reported a non-GAAP Earnings per Share(EPS) of -6. The EPS increased by 62.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125.23% | ||
| ROE | -214.1% | ||
| Debt/Equity | 0 |
NRBO Ownership
NRBO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.8 | 398.492B | ||
| AMGN | AMGEN INC | 16.04 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.4 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.21 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.95 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.01 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.29 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.95 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 340.74 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NRBO
Company Profile
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
Company Info
IPO: 2016-08-05
NEUROBO PHARMACEUTICALS INC
545 Concord Avenue, Suite 210
Cambridge MASSACHUSETTS 02116 US
CEO: Richard Kang
Employees: 8
Phone: 18577029600
NEUROBO PHARMACEUTICALS INC / NRBO FAQ
Can you describe the business of NEUROBO PHARMACEUTICALS INC?
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2016-08-05. The company is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
What is the stock price of NEUROBO PHARMACEUTICALS INC today?
The current stock price of NRBO is 2.36 USD. The price increased by 0.43% in the last trading session.
Does NEUROBO PHARMACEUTICALS INC pay dividends?
NRBO does not pay a dividend.
How is the ChartMill rating for NEUROBO PHARMACEUTICALS INC?
NRBO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about NEUROBO PHARMACEUTICALS INC (NRBO) stock?
8 analysts have analysed NRBO and the average price target is 27.2 USD. This implies a price increase of 1052.54% is expected in the next year compared to the current price of 2.36.
What sector and industry does NEUROBO PHARMACEUTICALS INC belong to?
NEUROBO PHARMACEUTICALS INC (NRBO) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for NEUROBO PHARMACEUTICALS INC?
NEUROBO PHARMACEUTICALS INC (NRBO) has a market capitalization of 20.34M USD. This makes NRBO a Nano Cap stock.